Tunable and Multifunctional Eukaryotic Transcription Factors Based on CRISPR/Cas

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation

Published Version
doi:10.1021/sb400081r

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11878858

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Tunable and Multifunctional Eukaryotic Transcription Factors Based on CRISPR/Cas

Fahim Farzadfard, †‡§ Samuel D. Perli, †‡ and Timothy K. Lu*, †‡§∥

†Department of Electrical Engineering & Computer Science and Department of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
‡MIT Synthetic Biology Center, 500 Technology Square, Cambridge, Massachusetts 02139, United States
§MIT Microbiology Program, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
∥Biophysics Program, Harvard University, Cambridge, Massachusetts 02139, United States

Supporting Information

ABSTRACT: Transcriptional regulation is central to the complex behavior of natural biological systems and synthetic gene circuits. Platforms for the scalable, tunable, and simple modulation of transcription would enable new abilities to study natural systems and implement artificial capabilities in living cells. Previous approaches to synthetic transcriptional regulation have relied on engineering DNA-binding proteins, which necessitate multistep processes for construction and optimization of function. Here, we show that the CRISPR/Cas system of Streptococcus pyogenes can be programmed to direct both activation and repression to natural and artificial eukaryotic promoters through the simple engineering of guide RNAs with base-pairing complementarity to target DNA sites. We demonstrate that the activity of CRISPR-based transcription factors (crisprTFs) can be tuned by directing multiple crisprTFs to different positions in natural promoters and by arraying multiple crisprTF-binding sites in the context of synthetic promoters in yeast and human cells. Furthermore, externally controllable regulatory modules can be engineered by layering gRNAs with small molecule-responsive proteins. Additionally, single nucleotide substitutions within promoters are sufficient to render them orthogonal with respect to the same gRNA-guided crisprTF. We envision that CRISPR-based eukaryotic gene regulation will enable the facile construction of scalable synthetic gene circuits and open up new approaches for mapping natural gene networks and their effects on complex cellular phenotypes.

KEYWORDS: synthetic transcription factors, CRISPR/Cas9, RNA-guided multiplex gene regulation, synthetic gene regulation, endogenous gene regulation, synthetic biology

Complex and sophisticated phenotypes in eukaryotic cells manifest from layered regulatory networks and specific expression programs involving the regulated transcription of many genes.1 As major players in these networks, eukaryotic transcriptional factors (TFs) can integrate multiple signals and perform complex, combinatorial functions on promoters, where regulatory information is encoded in the form of binding sites for TFs and interactions between TFs, to modulate gene expression patterns.1−3

Rewiring endogenous transcriptional networks by natural or synthetic TFs is a powerful strategy for interrogating cellular functions and controlling cellular phenotypes.4−14 Previously, natural DNA-binding domains (DBDs, mainly from bacterial sources, such as TetR, LacI, and LexA) have been used to recruit effector (e.g., activator and repressor) domains to the regulatory regions of eukaryotic genes in order to modulate their transcription.15−17 This necessitates the placement of DBD-specific operator site(s) in the cis-regulatory region of the promoters for specific genes which is a labor- and time-intensive process, especially if the regulation of multiple genes is desired. Moreover, engineering and modulating complex transcriptional networks requires tunable, extensible, and orthogonal transcription factors. However, only a few orthogonal variants of natural DBDs are well-characterized and changing their specificity has proven to be challenging.18 As such, the use of natural DBD-based TFs for wiring complex transcriptional networks and synthetic gene circuits has been limited.

To address these limitations, synthetic TFs based on Zinc Fingers (ZF s) and Transcriptional Activator-Like Effectors (TALEs) have been developed.19−25 The ability to program the specificity of ZFs and TALEs to potentially target any sequence makes these DBDs appealing for designing libraries of orthogonal transcription factors. Synthetic ZF- and TALE-based TFs have been shown to work in a wide range of...
eukaryotes;22,26,27 however, obtaining a TF for a given target site requires tedious selection processes or multistage DNA assembly protocols.28,29 Furthermore, the scale of regulation that can be achieved by these TFs is potentially limited by the metabolic burden imposed on the cells and the number of TFs that can be simultaneously encoded in a given cell.30

Here, we present a strategy for modulating eukaryotic transcription at natural and synthetic promoters using programmable and tunable synthetic transcription factors based on a bacterial CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas system. Many bacteria use CRISPR-based immune systems to degrade genetic materials of invading phages.31,32 In these systems, short RNAs expressed from CRISPR loci are used to target an endonuclease protein (Cas9) against invading genetic material. Recently, it has been shown that Cas9 can be used as a programmable tool for genome editing across various organisms.33−38 In this context, small customizable guide RNAs (gRNAs) can be used to program and target Cas9 endonuclease to specific loci in living cells to induce double (or single)-stranded breaks in DNA. Upon cleavage, error-prone or template-directed repair pathways are triggered, generating variants of the original target loci.39

Recently, Qi et al.39 showed that an endonuclease-deficient Cas9 (dCas9, with D10A H841A mutations relative to the wild-type Cas9) can be used as a programmable “CRISPRi” tool for gene silencing in Escherichia coli. When targeted to a promoter or ORF of a gene of interest, dCas9 can block progression of RNA polymerase and hence silence expression of the targeted gene. They also provided evidence that CRISPRi is functional in human cells, albeit with much lower efficiency compared with E. coli. In addition, Bikard et al. demonstrated that along with programmed transcriptional repression, transcriptional activation can be achieved in E. coli by fusing the omega subunit of RNA polymerase to the endonuclease-deficient Cas9.40

Here, we achieved versatile, programmable, and multiplexable tools for gene regulation in eukaryotes by functionalizing...
ing dCas9 with effector domains and targeting both natural and synthetic promoters. As a proof of concept, we made an RNA-guidable transcription factor by fusing dCas9 to an activator domain. Using this CRISPR-based transcription factor (crisprTF), we teased apart the regulatory maps of several natural eukaryotic promoters (in \textit{Saccharomyces cerevisiae} and HEK293T cells) without the need to modify promoter architectures. Unlike previous generations of customizable DBDs (i.e., ZFs and TALEs) that require multistage design and cloning strategies, crisprTFs can be readily customized and retargeted to different loci and regulatory regions \textit{in vivo} using specific gRNAs with homology to target sites (Figure 1). dCas9 thus offers a powerful tool for targeting functions of interest to specific genomic loci in living cells, which can potentially be used to regulate gene expression at will, construct scalable synthetic gene circuits, or rewire endogenous regulatory networks.

To implement crisprTFs in \textit{Saccharomyces cerevisiae}, we fused the SV40 nuclear localization sequence (NLS) and four tandem copies of Herpes Simplex Viral Protein 16 (VP64, a commonly used eukaryotic transcription activator domain) to a codon-optimized \textit{S. pyogenes} dCas9 (Figure 1A).

**Figure 2.** Regulation of \textit{yfp} expression from a minimal MLP promoter (pMLPm) by crisprTFs in HEK293T cells. (A) dCas9-VP64 is expressed in HEK293T cells by the pCMV promoter and directed to target sequences in pMLPm. The mKATE (red) and mBFP2 (blue) fluorophores act as flow-cytometry gating controls for successful plasmid transfections. (B) Map of pMLPm illustrating the relative positions of known regulatory elements. Blue lines indicate target sites for each gRNA. (C) Regulation of \textit{yfp} expression from pMLPm by crisprTFs based on the gRNAs shown in (B). HEK293T cells were cotransfected with the plasmids shown in (A), with specific gRNAs labeled as shown in the x-axis. Targeting crisprTFs to sequences upstream of the TATA box (by m1, m2, m6, and m7 gRNAs) resulted in higher \textit{yfp} expression compared with the no gRNA control. Error bars indicate the standard error of the mean for three independent biological replicates. Asterisks (*) on each bar indicate statistically significant changes in \textit{yfp} expression relative to the no gRNA control (based on the two-sided Welch’s t test, \textit{p}-value <0.05).
the TATA box and the transcription start site (using c2 and c6 gRNAs), likely due to interference of crisprTFs with the formation of the transcriptional initiation complex. No activation was observed with any of the eight tested gRNAs when dCas9, without a fused activator domain, was targeted to pCYC1m (Figure S1, Supporting Information). All the tested gRNAs in this strain repressed gfp expression to some extent (Figure S1, Supporting Information), with highest repression observed with c6 and c7. These results demonstrate that dCas9 is able to repress transcription but requires an activation domain (VP64) to activate transcription of a target locus and further supports the hypothesis that dCas9 (or as a fusion to VP64) can act as a repressor by interfering with the formation of the transcriptional initiation complex. Similar results were achieved with the GAL1 promoter (pGAL1) and its variants, where targeting crisprTFs to sequences upstream and downstream of TATA box led to activation and repression of the GFP reporter, respectively (Figure S2, Supporting Information). These results indicate that a single crisprTF can be programmed to act as both an activator and a repressor by targeting it to different positions across endogenous promoters.

The activity of a promoter is determined by combinatorial interactions between transcriptional regulatory factors bound to that promoter. We thus investigated the effects of binding of multiple crisprTFs targeted to the same promoter. To this end, pairwise combinations of gRNAs with non-neutral effects (those that showed either activation or repression in the left panel of Figure 1C) were coexpressed. As shown in the right panel of Figure 1C, coexpression of repressor gRNAs resulted in synergistic repression of the reporter (up to 7× repression was achieved with coexpression of the c5 and c6 pair as well as the c6 and c7 pair). On the other hand, when a repressor gRNA was coexpressed with an activator gRNA (e.g., the c3 and c6 pair), an intermediate level of GFP expression was achieved, indicating an antagonistic interaction between the two gRNAs. Moreover, the effects of repressor gRNAs were dominant over activator gRNAs, suggesting that interruption of the formation of the transcriptional initiation complex has a stronger effect than activation. Coexpression of two activator gRNAs (e.g., c3 and c4) did not result in synergistic activation of the reporter, which suggests that the relative positions and interactions of bound activators are important for determining synergistic activation. Consistent with our results, it has been shown that synergistic activation from synthetic promoters with multiple GAL4 operator sites depends on the distance and helical phase of the operator sites. Furthermore, in another study it has been shown that not all of the combinations of TALE-activators to the CCAAT box or the GC-boxes resulted in significant repression of the reporter, suggesting that interruption of the formation of the transcriptional initiation complex has a stronger effect than activation. Coexpression of two activator gRNAs (e.g., c3 and c4) did not result in synergistic activation of the reporter, which suggests that the relative positions and interactions of bound activators are important for determining synergistic activation. Consistent with our results, it has been shown that synergistic activation from synthetic promoters with multiple GAL4 operator sites depends on the distance and helical phase of the operator sites. Furthermore, in another study it has been shown that not all of the combinations of TALE-activators to the CCAAT box or the GC-boxes resulted in significant repression of the reporter, suggesting that interruption of the formation of the transcriptional initiation complex has a stronger effect than activation.

We next sought to investigate the activity of crisprTFs in human cells. To this end, a human-codon-optimized crisprTF cassette was placed on a plasmid under the control of the constitutive cytomegalovirus immediate-early promoter (pCMV). The gRNAs were expressed constitutively from a separate plasmid by the RNA polymerase III-dependent U6 promoter (pU6), as previously described (Figure 2A). After transfection of these plasmids into HEK293T cells, we investigated the regulatory architecture of the minimal adenovirus major late promoter (pMLPm) by targeting crisprTFs to different positions across this promoter (Figure 3A). YFP was used as the readout for pMLPm promoter activity.

Consistent with the results obtained in S. cerevisiae, crisprTFs activated gene expression when targeted to sequences upstream of the pMLPm TATA box (using m1, m2, m6, or m7 gRNA) or downstream of the transcription start site (m8 gRNA) (Figure 2B and C). Since the basal expression level of the pMLPm promoter is low, it was challenging to detect significant repression from this promoter. Thus, to demonstrate that crisprTFs can function as transcriptional repressors in mammalian cells, we placed mKATE under the control of a constitutive mammalian promoter, phosphoglycerate kinase 1 (pPGK1), and targeted crisprTFs to this promoter (Figure 3A). pPGK1 is a strong, constitutive, TATA-less promoter that contains a CCAAT box and five GC-boxes. These sites are the binding sites for the endogenous human transcription factors CBP and SP1, respectively. Targeting dCas9 alone, dCas9 fused to VP64 domain, or dCas9 fused to KRAB domain to the CCAAT box or the GC-boxes resulted in significant repression of the reporter gene (Figure 3B), presumably by preventing endogenous transcription factors from binding to specific DNA recognition elements within the pPGK1 promoter.

We further sought to explore the tunability of crisprTFs in the context of synthetic promoters. In order to do so, we engineered multiple artificial binding sites (operators), pCYC1m separated by 20 base-pair sequences, upstream of the pCYC1m promoter in S. cerevisiae (Figure 4A). Expression of a gRNA, which targeted these arrayed operator sites resulted in synergistic activation of the bfp reporter (Figure 4B). Higher levels of bfp expression (up to 70-fold activation with 12× gRNA operator sites) were achieved by increasing the number of gRNA binding sites upstream of the engineered pCYC1m. This level of activation in yeast is comparable to the activation reported for commonly used endogenous yeast promoters (e.g.,
Bacterial DNA binding domains (e.g., dCas9) and artificial transcription factors (crisprTFs) are rapidly becoming powerful tools to control gene expression in both prokaryotic and eukaryotic cells. To extend crisprTFs to eukaryotic cells, we aimed at engineering synthetic promoters and gRNAs that are orthogonal with respect to each other, e.g., to prevent activity at another locus. We aimed at determining the sequence specificity of Cas9 and its dependence on the PAM motif (NGG) and the 12 base-pairs preceding this motif. We also aimed at demonstrating the external control of crisprTFs by this means.

**Synergistic and tunable activation of synthetic promoters**

In many applications, control of the activity of a transcription factor by an inducer (e.g., a small molecule) is desired. With crisprTFs, one viable strategy is to constitutively express the protein component of the system (i.e., dCas9) and then modulate the amount of gRNA available for binding to dCas9 and thus the activity achieved at the target DNA. To test this strategy, we constructed an anhydrotetracycline (aTc)-inducible pRPR1 promoter by placing a TetR operator site (1xTetO) in the pRPR1 promoter, as previously described, and constitutively expressing Tet repressor (TetR) (Figure 5A). Furthermore, to make the expression of dCas9_VP64 independent of aTc, we placed it under the control of pGAL1. We tested this system in cells containing a pCYC1m promoter with six a1_gRNA operator sites, named 6x(a1_op)_pCYC1m, controlling expression of bfp. As shown in Figure 5B, bfp expression increased about 20-fold when *S. cerevisiae* cells were induced with galactose and aTc, compared with galactose only, thus demonstrating external control of crisprTF activity.

Although the exact parameters that determine the specificity of Cas9 are not yet well-characterized, it has been shown that the specificity of Cas9 for target loci is mainly determined by the PAM motif (NGG) and the 12 base-pairs preceding this motif (seed sequence). Mutations in any of these 15 positions can severely affect the targeting efficiency and binding specificity of Cas9. To test whether this property can be used to create orthogonal synthetic promoters, new PAM motifs or single or multiple point mutations (marked with asterisks, Figure 6A) were introduced into the wild-type pCYC1m sequence to design a modified pCYC1m promoter (pCYC1m(modified), Figure 6A). As shown in the left panel of Figure 6B, the modified promoter did not respond to the wild-type gRNAs (except for c4, which still perfectly matched target sites within this modified promoter). However, this modified promoter responded to a new set of gRNAs (cm1, cm2, and cm5) that were designed to match the modified target sites. This demonstrated that as little as a single base-pair mismatch is sufficient to direct the crisprTF to one locus while preventing activity at another locus.

To further demonstrate the potential of crisprTFs toward constructing synthetic promoters and gRNAs that are orthogonal with respect to each other, we tested three randomly designed gRNAs (a1, a2 and a3 gRNAs) for their ability to activate each other’s target sequences. As shown in Figure 6C, each of the gRNAs exhibited high activity at their cognate target sequences but low activity at noncognate sequences. These results suggest that one can construct synthetic promoters and gRNAs that are orthogonal with respect to each other and to the host genome, especially within eukaryotes with smaller genomes, such as yeasts.

**Engineering of gRNA-binding sites**

During the course of the peer-review for this work, similar systems for transcriptional control in eukaryotic cells were described. Gilbert et al. demonstrated that CRISPR-mediated gene repression and activation can be achieved in both yeast and mammalian cells by using fusions of dCas9 with repressor and activator domains respectively. Furthermore, Maeder et al. and Perez-Pinera et al. showed synergistic CRISPR/Cas-based gene activation in human cells with multiple gRNAs. In this paper, we additionally show that both activation and repression of synthetic promoters can be introduced simultaneously by using synthetic double-stranded gRNAs.
directing a single protein to different positions of a promoter is advantageous for the efficient design of synthetic transcriptional networks or rewiring natural ones. This property obviates the need for using separate orthogonal Cas9 protein fusions as activators and repressors. Furthermore, we demonstrate that more sophisticated regulatory motifs, such as small-molecule responsive modules can be built for crispTFs, thus enabling external control of crispTF-based transcriptional circuits. Such synthetic modules can be interfaced with other regulatory elements to achieve more complex regulation for synthetic biology.

Our results show that dCas9 can be used as a customizable RNA-guided DNA-binding platform for the regulation of gene expression at natural and synthetic promoters in eukaryotic cells. The ease of design and expression of customized gRNAs in comparison to ZFs and TALEs make CRISPR-based transcription factors appealing as synthetic TFs for modulating endogenous gene expression as well as for synthetic biology. The ability to customize the target site of dCas9 via the expression of short gRNAs obviates the need to engineer multiple orthogonal DBDs in order to construct complex transcriptional circuits. This could potentially reduce the overall metabolic burden on cells and enable the integration of more complex synthetic computation and logic within living cells. More complex regulatory and logic circuits, such as cascades and complex digital logic gates can be built by layering crispTFs. The possibility of integrating multiple inputs at a single promoter expands the regulatory potential and provides us with increased flexibility that can be leveraged while designing synthetic transcriptional networks or rewiring endogenous pathways.

Furthermore, since both activation and repression functions can be achieved with crispTFs, the crispTF platform may be advantageous compared to noncoding RNA-based gene regulatory platforms where only repression can be achieved. In a way, crispTFs combine the multiplexability of RNA-based regulatory approaches with the flexibility and rich functionality repertoire of protein-based gene regulatory approaches: Cas9 can be functionalized with regulatory domains of interest (e.g., activation, repression, or epigenetic effectors) and then be targeted to multiple loci using different gRNAs.

Future work is needed to define the range of effector domains that can be used with dCas9 for a variety of regulatory functions, including transcriptional regulation and epigenetic modifications. In addition, the identification, characterization, and optimization of Cas9 homologues or evolved variants may enable enhanced activity and specificity of this system. Moreover, the ability to synthesize random libraries of gRNAs opens the possibility for high-throughput perturbations of transcriptional networks and screening for desirable phenotypes. Ultimately, we envision that crispTFs will enable the regulation and perturbation of natural transcriptional networks as well as the construction of complex synthetic circuits at an unprecedented speed and scale.

## METHODS

**Strain and Plasmid Construction.** Saccharomyces cerevisiae. dCas9 (endonuclease-deficient Cas9, with D10A and H841A mutations relative to the wild-type sequence of S. pyogenes Cas9) with an N-terminal SV40 nuclear localization signal (NLS) was codon-optimized for expression in S. cerevisiae and cloned into a pRS314 backbone under control of the pTPGI promoter. The RNA-guided transcription factors (crispTFs) were built by fusioning four repeats of the minimal domain of the herpes simplex viral protein 16 (VP16) to the C-terminus of dCas9 (dCas9 VP64). The crispTF-expressing plasmid was then integrated into the TRP1 locus of S. cerevisiae W303.

The reporter plasmids were built by cloning yeast-enhanced gfp under the control of the wild-type or modified pCYC1m promoter into pRS406 using one-step Gibson assembly. The reporters for the multiple-gRNA-binding-site experiment (Figure 4A) were built by cloning the corresponding number of binding sites upstream of the pCYC1m promoter driving production of EBFP2. All reporters were integrated into the bfaI locus of the integrated crispTF plasmid.

To build gRNA-expressing plasmids, empty gRNA expressing vectors were first made by cloning the pPR1 promoter (an RNA-polymerase-III-dependent promoter), the gRNA handle (flanked by HindIII and XhoI sites), and the RPR terminator.
Figure 6. Constructing orthogonal crisprTF-responsive promoters. (A) A schematic view of gRNAs targeting the wild-type and modified pCYC1m promoters in yeast. Only the c1-c8 gRNAs have perfect homology to the target sequences in pCYC1m. On the other hand, c1, c4, c5, and cm1-cm6 gRNAs have perfect homology to the sequences in the pCYC1m(modified) promoter. Mismatches between pCYC1m and pCYC1m(modified) are marked by asterisks (*). (B) pCYC1m only responds to gRNAs that are perfectly matching gRNAs (c1-c8 gRNAs) and not to those that contain mismatches (cm1-cm6 gRNAs). The pCYC1m(modified) promoter responds to the cm1-cm6 gRNAs. Those gRNAs that bind to the sequences upstream of the TATA boxes activate gfp expression and those that target sequences downstream of the TATA boxes repress gfp expression. The c1 and c5 gRNAs have similarly neutral effects on both the wild-type and modified promoters. Error bars indicate standard error of the mean for three independent biological replicates. Asterisks (*) on each bar indicate statistically significant activation or repression relative to no gRNA controls (based on the two-sided Welch’s t test, p-value < 0.05). (C) Heat map illustrating the orthogonality of crisprTFs in human cells. Plasmids encoding three orthogonal gRNAs (a1, a2, and a3 gRNAs) were cotransfected into HEK293T cells along with one of the three reporter plasmids (each encoding 4x operator sites for a given gRNA) upstream of pMLPm promoter driving yfp expression. Only cognate interactions between gRNAs and target binding sites resulted in significant activation. The standard error of the mean of YFP fluorescence for three independent biological replicates is indicated in each cell of the heat-map plot.
Research Article

HEK293T Cells. To construct the mammalian dCas9_VP64 expressing plasmid, we first introduced D10A and H841A mutations into hCas9 (Addgene, Plasmid #41815). Then, three repeats of SV40 NLS (3×NLS) were fused to the C-terminus of the mutated hCas9 using a PCR-based assembly protocol. Using a multipart Gibson assembly protocol, the immediate-early promoter of cytomegalovirus (pCMV), dCas9_3xNLS, VP64, and SV40 polyA terminator were cloned into the NotI site of the pGS-Luc plasmid (Promega). To monitor successfully transfected cells by flow cytometry, we replaced the original luciferase gene in pGS-Luc with mKATE (Evrogen). The resulting pPGK1_mKATE cassette served as a constitutive fluorescent protein control that was used to gate for the presence of the crisprTF-expressing plasmid with flow cytometry.

The gRNA expression plasmids were constructed by cloning the 138 bp human U6 promoter (an RNA-polymerase-III-dependent promoter)8), along with the gRNA handle and terminator into a plasmid containing pPGK1-eBFP2 flanked by the SV40 polyA terminator (a gift from Lior Nissim). A SacI site was placed at the 3′-end of the U6 promoter to enable the cloning of different specificity determining sequences for each gRNA. The reporters were assembled into the gRNA-expressing plasmid through a one-step Gibson assembly reaction, where the upstream polyadenylation signal and transcriptional pause site from pGS-Luc, along with a 41 bp, minimal adenovirus type 2 major late promoter (pMLPm), mYFP, and HSV polyA signal were cloned into the AatII site of the gRNA-expressing plasmids.

For the synthetic promoter experiments, additional gRNA operator sites were cloned in the Nhel site upstream of the pMLPm promoter (see Supporting Information). For the repression experiments, dCas9_KRAB was constructed by cloning a 366 bp KRAB domain to the C-terminus of dCas9. GCCACC was used as the Kozak sequence for the expression of dCas9_VP64, mYFP, eBFP2, and mKATE. Unless directly targeted by gRNAs for repression assays, the mKATE fluorescent protein on the crisprTF-expression plasmid and the eBFP2 fluorescent protein on the reporter/gRNA plasmid served as our gating controls for flow cytometry analysis.

Fluorescence Assays. To assess expression of the reporter constructs, yeast cells expressing different gRNAs (or no gRNA as control) were grown overnight (900 rpm, 30°C) in 96-deep-well plates in yeast minimal media supplemented with glucose with appropriate selection (three independent cultures for each sample). Ten microliters of these cultures were then transferred into fresh media supplemented with galactose +250 ng/mL anhydrotetracycline (aTc) and grown for 20 h (900 rpm, 30°C) before analysis by flow cytometry.

For the human cell culture experiments, HEK293T kidney epithelial cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 1% glutamine, and 1% penicillin/streptomycin. Cells were grown under 5% CO2 at 37 °C. HEK293T cells were transfected with Fugene-HD transfection reagent (Promega) and assayed for gene expression with flow cytometry at 48 h post transfection.

An LSR Fortessa II flow cytometer equipped with 405 nm, 488 nm, and 561 nm lasers was used for all the experiments. GFP/YFP, BFP, and mKATE levels were detected using 488/ FITC, 405/Blue, and 561/TX-red laser/filter sets, respectively. All samples were uniformly gated by forward and side scatter. Additional gating for the presence of red and blue fluorophores was applied to the HEK293T samples to ensure only cells successfully transfected with both the crisprTF and the reporter/gRNA plasmids are analyzed. For each gated sample, the mean fluorescence per cell was calculated. Three independent biological samples were used to calculate the mean and standard error of the mean for each data point.

ASSOCIATED CONTENT

Supporting Information
This information is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author
E-mail: timlu@mit.edu.

Author Contributions
F.F. built and tested the yeast crisprTF system. S.D.P. built and tested the human crisprTF system. F.F., S.D.P., and T.K.L. designed experiments, analyzed data, and wrote the paper.

Notes
The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by the Defense Advanced Research Projects Agency, the National Institutes of Health New Innovator Award (1DP2OD008435), and the National Science Foundation (1124247).

REFERENCES


